CHEK2 encodes for a G2 checkpoint kinase which plays a critical role in DNA repair. Its mutation confers an increased risk of breast cancer. It has also been suggested to increase risks of prostate cancer, but its involvement with this type of cancer has not been confirmed.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
We performed a systematic review and meta-analysis to clarify the association between CHEK2 1100delC, IVS2+1G>A, I157T mutation and risk of Prostate Cancer. A comprehensive, computerized literature search of PubMed until December 27, 2014 was carried out. Eligible studies were included according to specific inclusion criteria. Pooled hazard ratio was estimated using the fixed effects model or random effects model according to heterogeneity between studies.
Eight eligible studies were included in the analysis, all were retrospective studies. The overall meta-analysis demonstrated that the CHEK2 1100delC mutation (OR 3. 29; 95% confidence interval: 1. 85-5. 85; P = 0. 00) and I157T missense mutation (OR 1. 80; 95% confidence interval: 1. 51-2. 14; P = 0. 00) was associated with higher risk of Prostate Cancer, and CHEK2 1100delC mutation is irrelevant to familial aggregation phenomenon of prostate cancer (OR 1. 59; 95% confidence interval: 0. 79-3. 20; P = 0. 20). The IVS2+1G>A mutation is also irrelevant to Prostate Cancer (OR = 1. 59, 95% CI = 0. 93-2. 71, P = 0. 09). None of the single studies materially altered the original results and no evidence of publication bias was found.
CHEK2 1100delC mutation and I157T missense mutation in males indicates higher risk of Prostate Cancer, but there's no evidence to prove the CHEK2 1100delC mutation was associated with Familial prostate cancer.
International journal of clinical and experimental medicine. 2015 Sep 15*** epublish ***
Yue Wang, Bo Dai, Dingwei Ye
Department of Urology, Fudan University Shanghai Cancer Center Shanghai 20032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 20032, China. , Department of Urology, Fudan University Shanghai Cancer Center Shanghai 20032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 20032, China. , Department of Urology, Fudan University Shanghai Cancer Center Shanghai 20032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 20032, China.